



## Review article

## Nodding syndrome: A key role for sources of nutrition?

P.S. Spencer<sup>a,b,\*</sup>, C. Okot<sup>c</sup>, V.S. Palmer<sup>a</sup>, R. Valdes Angues<sup>a</sup>, R. Mazumder<sup>d</sup><sup>a</sup> Department of Neurology, School of Medicine, Oregon Health & Science University, Portland, OR, USA<sup>b</sup> Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, OR, USA<sup>c</sup> Case-worker in Gulu, Uganda<sup>d</sup> Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, USA

## ARTICLE INFO

## Keywords:

Displacement  
Malnutrition  
Hypovitaminosis  
Pyridoxine  
Agaritine  
Tauopathy

## ABSTRACT

Nodding Syndrome (NS) has occurred among severely food-stressed communities in northern Uganda and several other East African populations that, with their forced physical displacement, have resorted to nutritional support from available wild plants and fungi, some of which have neurotoxic potential. Among the latter is an agaric mushroom with an unknown content of hydrazine-generating agaritine, namely *Agaricus bingensis*, the unusually wide consumption of which may relate to the low serum levels of vitamin B6 in Ugandan NS subjects relative to controls. Hydrazine-related compounds induce patterns of DNA damage that promote neuropathological changes (tauopathy) reminiscent of those associated with established NS. While the cause of this childhood brain disease is unknown, we encourage increased attention to the role of malnutrition and B6 hypovitaminosis in the etiology of this devastating brain disease.

## 1. Introduction

Nodding syndrome (NS) is a pediatric epileptic and apparently progressive encephalopathy of unknown etiology that has been present in several east African countries, including first-case reports in impoverished communities in Tanzania (1934), South Sudan (1991), Uganda (1994), Democratic Republic of Congo (2016), Cameroon (2018) and Central African Republic (2019), with possible cases in Liberia (1983). Currently estimated prevalence rates include 0.3% in Uganda, 0.4% in Democratic Republic of Congo, 0.7% in Tanzania and 4.6% in South Sudan [1]. Onset of head nodding, which precedes or accompanies convulsive seizures, occurs in 2–18-year-old children [2–5], more of whom than healthy controls were born pre-term and were infected with the nematodes *Onchocerca volvulus* and *Mansonella* spp. [4,6,7]. Five overlapping clinical stages have been described among Ugandan children with NS: prodromal (staring, inattention, dizziness, etc.), head nodding, convulsive seizures, multiple impairments, and severe disability [8]. NS is often accompanied by severe malnutrition and avitaminoses with skin changes, wasted muscles, stunted growth and marasmic-kwashiorkor stigmata accompanied by neuropsychiatric complaints, including slowed mentation, mental retardation and convulsions [9]. [8]. Developmental delay, tardy sexual development and seizures in NS [6] overlap with the clinical picture of Nakalanga

dwarfism [10]. Some longstanding Tanzanian subjects developed signs consistent with parkinsonism [11]. The neuropathology of mid-stage NS is dominated by tau-associated neuronal degeneration, notably in the pre-frontal cortex [12].

Nodding syndrome has been the subject of two recent systematic reviews that surveyed reports relating to NS etiology, including infections, malnutrition, toxins, autoimmune, hormonal, metabolic, genetic and psychiatric factors [1,13]. One hypothesis is that NS is a form of onchocerciasis-associated epilepsy [7] secondary to autoimmunity driven by molecular mimicry between tropomyosin in *O. volvulus* (OV) and leiomodulin-1 in brain tissue [14,15]. Autoimmune antibodies to three extracellular peptides of glutamate receptors have been reported in NS; patients' purified IgG antibodies induced seizure activity when released continuously in the brain of mice [16]. Specific amino acids in HLA-B have been proposed to convey disease susceptibility [17]. NS has shown both positive and negative associations with reported infection with measles virus (*Paramyxoviridae*) [6,18], and no association with several other virus families [19]. A small number of NS cases was found to have low levels of luteinizing hormone, follicle-stimulating hormone, testosterone and estrogen [20]. Metabolic changes reported in NS include low biotinidase and acetyl carnitine levels, normal urate levels [22] and a high-anion-gap metabolic acidosis [21]. Nodding Syndrome has been compared with wartime-induced Developmental Trauma

\* Corresponding author at: Oregon Health & Science University (Neurology), S.W. Sam Jackson Park Road, Portland, OR 97239, USA.

E-mail address: [spencer@ohsu.edu](mailto:spencer@ohsu.edu) (P.S. Spencer).

<https://doi.org/10.1016/j.ensci.2022.100401>

Received 12 January 2022; Received in revised form 1 April 2022; Accepted 7 April 2022

Available online 10 April 2022

2405-6502/© 2022 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Disorder [9].

Common to at least three foci of NS were population displacement and periodic food insecurity during which people resorted to food collected in the wild. Seasonal food shortages impacted the Wapagoro people of Tanzania, among whom NS was evident as far back as 1934 [11]. In NS-affected Moru communities of South Sudan, wild vegetables, fruit, mushrooms, grass, fish and bush meat were used to supplement emergency relief food, while the largely NS-free Dinka cattle herders had access to cows' milk [4]. Even in normal times, mushrooms and African winged termites ("white ants") are collected and sold for income by very poor households in parts of Uganda [23]. During the civil war (1991–2006) between the Ugandan government and the Lord's Resistance Army, 1.84 million Acholi people of northern Uganda were moved to 251 Internal Displacement Camps (IDP) [24] where emergency food (maize, sorghum, beans or yellow split peas, vegetable oil and Corn Soya for children) was provided, but supplies were often of extremely poor quality and even rotten [25]. Red sorghum (*serena*) provided by the World Food Program was weakly associated with NS in Sudan [4] but not in Uganda [26]. In Kitgum, a high-incident NS region in northern Uganda [27], rations were reduced to 60% for Non-Extremely Vulnerable Individuals [24]. Although being born in an IDP camp was not a risk factor for NS in Kitgum [7], many developed NS in that setting [28], peaking 5–7 years after their arrival [29]. In addition to significantly lower body weight, food dependence on moldy maize showed the strongest association with the onset of head nodding in a case-control study conducted in Kitgum's Tumangu Village [18]. However, in later years when former IDP residents had returned home and nutrition had improved, no difference was found in the mycotoxin content of urine from established NS cases and community controls [30,31]. However, since mycotoxins in urine reflect only the most recent (days) intake of contaminated food in subjects who developed NS years earlier [31], these studies do not exclude a role for mycotoxins (notably genotoxic aflatoxins) in the etiology of NS [30].

## 2. B6 hypovitaminosis

Food insecurity is often associated with vitamin deficiency. The serum pyridoxal-5'-phosphate (PLP) level was markedly lower than European standards in Tanzanian teenagers with established NS or generalized epilepsy, but comparable to community controls twice their age [32]. A 2009 Centers for Disease Control and Prevention-led case-control study of NS in Kitgum, Uganda, found a majority of recent NS cases (84%) and controls (75%) had low vitamin B6 (PLP) levels [26]. A 2016 Ugandan study noted that established NS cases ( $n = 66$ , mean age 12.5 years) had an average vitamin B6 concentration 2.5 times lower than that of healthy controls ( $n = 73$ , mean age 8.9 years), while the mean plasma level of 3-hydroxykynurenine (3-HK), a potentially neurotoxic molecule, was 10 times higher in NS cases than in controls [28]. Importantly, perturbations of the kynurenic pathway have been linked to epilepsy and progressive neurodegenerative disease [33,34], particularly Alzheimer's disease (AD) [35], with which NS has been compared [36]. While adults are relatively tolerant of vitamin B6 deficiency, parents weaning children on relief food (a marker of food insecurity) were more likely to experience NS than children fed on home-grown food [28]. Of note, certain filarial nematode parasites resident in pyridoxine-deficient animal hosts may have reduced PLP uptake resulting in lowered glycogen phosphorylase activity and impaired muscle cell glycogenolysis; this results in fewer and smaller adult worms and impaired production of microfilariae [37]. Given that whole families were interred in IDP camps or otherwise subject to harsh wartime conditions, one would anticipate that a nutrition/food-related disorder would affect more than a single family member. Indeed, in northern Uganda, Kitgum families had multiple children with and without NS [3]. While electroencephalogram (EEG) study of Kitgum teenagers with NS showed ictal high-amplitude slow waves with superimposed fast activity, abnormal interictal epileptiform abnormalities were also found in

younger healthy siblings [38] that suggested subclinical NS-related brain damage. Of interest is that pyridoxine-dependent and pyridoxal phosphate-dependent epilepsy may present as West Syndrome, an epilepsy syndrome of infancy with epileptic spasms, where the seizure semiology may present as head nodding [39]. In pyridoxine-dependent epilepsies among infants, the EEG shows paroxysmal runs of 1–4 Hz bilaterally synchronous sharp and slow-wave activity [40]. This pattern resembles the atypical slow spike-and-wave activity seen interictally among children with NS [41]. Clinical studies have also found that epileptic spasms form a predominant ictal electroclinical pattern in pyridoxine-dependent epilepsies [42].

## 3. Sources of food

The question therefore arises as to the sources of nutrition (other than emergency food relief) in food-insecure populations at risk for NS. Among Acholi people in the disease epicenter of northern Uganda, onset of head nodding was most frequent between March and September, when crop production was low and feeding families was challenging [18]. Wild mushrooms are of special interest because they may harbor natural compounds with toxic potential. The Acholi people normally collect mushrooms (*obwol*) from anthills, forests, gardens, from decomposing tree trunks, and from fresh-growing grass; they are named depending on the season of the year in which they commonly grow. Wild mushrooms consumed by the Acholi include a species of *Termitomyces* that grows symbiotically on termite nests ("anthills") and is mainly harvested in August and September; the mushroom is considered by local people to be non-poisonous, and a similar species lacked acute and subchronic toxicity at levels tested in laboratory rats [43]. Other species, such as *T. robustus* and *T. striatus*, reportedly harbor an unknown heat-labile substance that does not support growth and may be toxic to rats [44].

Ingestion of certain mushrooms (specifically *Agaricus bisporus*, *Gyromitra esculenta*) can depress vitamin B6 levels, and that depletion can result in abnormal EEG patterns and intractable seizures [45], although none of the NS cases reportedly was consuming the aforementioned mushrooms at the time of a 2016 Ugandan study of this disorder [28]. However, *A. bingensis* Heinem., a species known only from Africa (Bénin, Democratic Republic of the Congo, Togo, Uganda) [46,47], is gregarious around termite mounds in Western and Northern Uganda, where in particular it is used as a source of food by the Acholi people [48]. Known in Kitgum, Uganda, by the local name *Ayaa kum Got*, the fungus is collected in the rainy season (from March onward) and mainly cooked and eaten by elderly women in the high-incidence NS focus of Tumangu. Among young people, this mushroom is believed by community elders to cause deafness and mental confusion – the latter reminiscent of the prodromal stage of NS. Some communities also believe that ingestion of *Ayaa kum Got* can cause barrenness among young women, and therefore women of reproductive age are prohibited from eating the mushroom. However, in food-insecure, famine-prone IDP camps, people (especially in Kitgum) reported that women harvested and prepared the mushroom for the whole family to eat, including young children. Noteworthy is that vitamin B6 is involved in the regulation of mental function and mood [49], and pyridoxine has been used successfully to treat deafness [50].

## 4. Hydrazinic fungi

All species of *Agaricus* mushrooms harbor the water-soluble phenylhydrazine agaritine ( $N^2$ -( $\gamma$ -L-glutamyl)-4-hydroxymethylphenylhydrazine), levels of which in wild agarics range from 100 to 10,000 mg  $kg^{-1}$  fresh weight compared to 200–500 mg agaritine  $kg^{-1}$  in cultivated *A. bisporus* samples that are sold for use as food worldwide [51,52]. Some agaric species in Africa are considered poisonous [44]. While levels of agaritine in *A. bingensis* are unknown, it is noteworthy that mushroom soup prepared from an unknown fungal species is recorded as

a pre-lacteal liquid given to Ugandan children in a nationwide survey with oversampling of IDP camps, where people were found to be most disadvantaged and children underweight for age [53]. No reference has been found to intoxication by *Gyromitra spp.*, other than isolated poisoning incidents in South Africa [44].

Agaritin is catalyzed in rat and mouse kidney homogenates by removal of the glutamyl group to yield reactive free hydrazine [54,55] which, after formylation to its corresponding hydrazone, may be activated both *in vitro* and *in vivo* to a methylating intermediate resulting in the formation of O<sup>6</sup>-methyl-(O<sup>6</sup>-mG) and N7-methylguanines (N7-mG) in DNA [56–58]. Additionally, 4-hydroxymethyl benzenediazonium salt, a carcinogen in *A. bisporus*, generates a carbon-centered radical, the 4-(hydroxymethyl)phenyl radical, which causes DNA strand breaks [59]. Similarly, methylazoxymethanol (MAM), the free-radical-generating aglycone of cycasin, increases DNA adducts (O<sup>6</sup>-mG, N7-mG) and elevates *tau* mRNA expression in rat neuronal cultures treated with glutamate [60] and, in mice, modulates brain cellular pathways involved in neurodegenerative disease and cancer in a DNA damage-linked manner [61,62]. MAM-β-D-glucoside (cycasin) is the principal toxin in cycad seed, the traditional food use of which by the Chamorro people of Guam is etiologically associated with the Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex, a tau-dominated polyproteinopathy that can begin early in life [63] and has a neuropathologic profile with some overlap with that of Nodding syndrome [12]. While there is some evidence that dietary B vitamin (B12, B6) supplementation can slow the advance of Mild Cognitive Impairment and AD [64,65], controlled studies with mouse models of human tauopathy show that chronic administration of a diet low in folate and B vitamins increases CNS homocysteine levels, which directly up-regulates the 5-lipoxygenase enzymatic pathway, thereby promoting tau phosphorylation, synaptic pathology, neuroinflammation, and behavioral deficits [66,67]. Taken together, therefore, there is a theoretical link between ingestion of hydrazinic compounds, depression of serum vitamin B6, and genesis of tauopathy. This may be of special relevance in the context of populations subject to protein-calorie malnutrition that by itself results in low vitamin B6 levels.

Several other features of NS [3,27,68,69] overlap with those associated with vitamin B6/PLP deficiency, namely: decreased ability to resist infection (nematodes? measles virus?) [70], reduced bone formation [71], cardiac dysrhythmia [72], sleep difficulties [73], swollen lips [74], anemia [75], peripheral muscle wasting [76], aggressive behavior [77], and hallucinations [78]. Vitamin B6 deficiency reduces the secretion of pituitary growth hormone [79] and mediators thereof (*i. e.*, Insulin-like Growth Factor and/or IGF binding protein-3) associated with the stunted growth, delayed bone age and delayed onset of puberty of children with NS [20]. Significantly, NS children diagnosed with Severe or Moderate Acute Malnutrition improved markedly when treated with multivitamins, local food supplements, anticonvulsants and psychosocial support; they gained weight and height, their seizure frequency and cognitive impairment were reduced, and their health condition and mental health status improved [80].

## 5. Conclusion

While the etiology of NS is unknown, the disease has affected infants and children of impoverished populations in which nematode infestation and food stress are significant factors, and in whom vitamin B6 levels are low. An autoimmune disorder is posited, but studies of cross-reactivity of OV and neuroproteins have yielded contradictory results [14,15,81], and OV antibody-negative NS cases are reported [82]. Displaced and food-insecure families used wild plants and mushrooms as emergency food. Eaten during periods of near-famine are mushroom species that would be rejected as food in normal times [44] or, in the case of *A. bingensis*, reserved for older people to consume. Considered inedible in NS-affected Tanzania [83], *A. bingensis* has an unknown content of the potentially genotoxic phenylhydrazine agaritin.

Hydrazinic compounds have the potential to lower vitamin B6 levels, generate DNA-damaging free radicals, and modulate neuronal tau expression, and one such compound (MAM) is linked with tau-related neuronal degeneration, the dominant neuropathology of mid-stage NS. Studies are needed to determine the agaritin content of wild *A. bingensis* in NS-affected areas (which include the Kabarole District of Western Uganda [84] where the mushroom is also consumed [48]), to establish the food-use patterns of this hydrazinic fungus in disease foci, to determine its acute and chronic neurotoxic potential (with respect to PLP and 3-HK), and assess whether it has a role in the etiology of NS and NS-related Nakalanga syndrome (NLS) [5,10,85]. This principle extends beyond NS in Uganda; for example, the brain disease has been recently reported in a poverty-stricken, food-insecure region of the Central African Republic [86], the location of the poisonous agaric mushroom *A. aurantioviolaceus* R. Helm [44]. Whether toxic or not, it is noteworthy that the NS/NLS-free Zulu people of South Africa claim that all edible mushrooms contain a poisonous principle when uncooked [44].

## Credit

PSS conceived and drafted the paper. CO and VSP contributed information on food use of mushrooms in Uganda and South Africa, respectively. RM contributed information on NS electroencephalography. All authors conducted field studies of Nodding syndrome in Sudan (PSS), Tanzania (PSS, VSP) and Uganda (CO, RM, RVA, PSS, VSP).

## Declaration of Competing Interest

The authors declare no competing interests.

## Acknowledgments

Funded by NIH grant R21 NS108355.

## References

- [1] G.O.E. Abd-Elfarag, A.W.D. Edridge, R. Spijker, M.B. Sebit, M.B. van Hensbroek, Nodding syndrome: a scoping review, *Trop. Med. Infect. Dis.* 6 (2021) 211, <https://doi.org/10.3390/tropicalmed6040211>.
- [2] S.F. Dowell, J.J. Sejvar, L. Riek, K.A. Vandemaele, M. Lamunu, A.C. Kuesel, E. Schmutzhard, W. Matuja, S. Bunga, J. Foltz, T.B. Nutman, A.S. Winkler, A. K. Mbonye, Nodding syndrome, *Emerg. Infect. Dis.* 19 (2013) 1374–1384, <https://doi.org/10.3201/eid1909.130401>.
- [3] R. Idro, R.O. Opoka, H.T. Aanyu, A. Kakooza-Mwesige, T. Piloya-Were, H. Namusoke, S.B. Musoke, J. Nalugya, P. Bangirana, A.D. Mwaka, S. White, K. Chong, A.D. Atai-Omoruto, E. Mworozzi, J. Nankunda, S. Kiguli, J.R. Aceng, J. K. Tumwine, Nodding syndrome in Ugandan children—clinical features, brain imaging and complications: a case series, *BMJ Open.* 3 (2013), e002540, <https://doi.org/10.1136/bmjopen-2012-002540>.
- [4] P.S. Spencer, K. Vandemaele, M. Richer, V.S. Palmer, S. Chungong, M. Anker, Y. Ayana, M.L. Opoka, B.N. Klaucke, A. Quarello, J.K. Tumwine, Nodding syndrome in Mundri county, South Sudan: environmental, nutritional and infectious factors, *Afr. Health Sci.* 13 (2013) 183–204, <https://doi.org/10.4314/ahs.v13i2.2>.
- [5] P.S. Spencer, R. Mazumder, V.S. Palmer, M.S. Pollanen, Nodding syndrome phenotypes, *Rev. Neurol. (Paris)* 175 (2019) 679–685, <https://doi.org/10.1016/j.neurol.2019.09.005>.
- [6] J.K. Tumwine, K. Vandemaele, S. Chungong, M. Richer, M. Anker, Y. Ayana, M. L. Opoka, D.N. Klaucke, A. Quarello, P.S. Spencer, Clinical and epidemiologic characteristics of nodding syndrome in Mundri County, southern Sudan, *Afr. Health Sci.* 12 (2012) 242–248, <https://doi.org/10.4314/ahs.v12i3.1>.
- [7] N. Gumisiriza, M. Kugler, N. Brusselaers, F. Mubiru, R. Anguzu, A. Ningwa, R. Ogwang, P. Akun, A.D. Mwaka, C. Abbo, R. Sekibira, A. Hotterbeekx, R. Colebunders, K. Marsh, R. Idro, Risk factors for nodding syndrome and other forms of epilepsy in northern Uganda: a case-control study, *Pathogens.* 10 (2021) 1451, <https://doi.org/10.3390/pathogens10111451>.
- [8] R. Idro, R. Ogwang, E. Kayongo, N. Gumisiriza, A. Lanyero, A. Kakooza-Mwesige, B. Opar, The natural history of nodding syndrome, *Epileptic Disord* 20 (2018), <https://doi.org/10.1684/epd.2018.1012>, 508–16.3.
- [9] S. Musisi, D. Akena, E. Nakimuli-Mpungu, C. Abbo, J. Okello, Neuropsychiatric perspectives on nodding syndrome in northern Uganda: a case series study and a review of the literature, *Afr. Health Sci.* 13 (2013) 205–218, <https://doi.org/10.4314/ahs.v13i2.3>.
- [10] K. Föger, G. Gora-Stahlberg, J. Sejvar, E. Ovuga, L. Jilek-Aall, E. Schmutzhard, C. Kaiser, A.S. Winkler, Nakalanga syndrome: clinical characteristics, potential

- causes, and its relationship with recently described nodding syndrome, *PLoS Negl. Trop. Dis.* 11 (2017), e0005201, <https://doi.org/10.1371/journal.pntd.0005201>.
- [11] P.S. Spencer, V.S. Palmer, L. Jilek-Aall, Nodding syndrome: origins and natural history of a longstanding epileptic disorder in sub-Saharan Africa, *Afr. Health Sci.* 13 (2013) 176–182, <https://doi.org/10.4314/ahs.v13i2.1>.
- [12] M.S. Pollanen, S. Onzivua, J. Robertson, P.M. McKeever, F. Olawa, L. Kitara, A. Fong, Nodding syndrome in Uganda is a tauopathy, *Acta Neuropathol.* (Berl.) 136 (2018) 691–697, <https://doi.org/10.1007/s00401-018-1909-9>.
- [13] H.J. Stacey, L. Woodhouse, S.C. Welburn, J.D. Jones, Aetiologies and therapies of nodding syndrome: a systematic review and meta-analysis, *J Global Health Rep.* 3 (2019), e2019066, <https://doi.org/10.29392/joghr.3.e2019066>.
- [14] T.P. Johnson, R. Tyagi, P.R. Lee, M.H. Lee, K.R. Johnson, J. Kowalak, A. Elkahoun, M. Medynets, A. Hategan, J. Kubofcik, J. Sejvar, J. Ratto, S. Bunga, I. Makumbi, J. R. Aceng, T.B. Nutman, S.F. Dowell, A. Nath, Nodding syndrome may be an autoimmune reaction to the parasitic worm *Onchocerca volvulus*, *Sci. Transl. Med.* 9 (2017) eaaf6953, <https://doi.org/10.1126/scitranslmed.aaf6953>.
- [15] D.W. Nauen, M.C. Haffner, J. Kim, Q. Zheng, H. Yin, A.M. DeMarzo, V. Mahairaki, C. Colantuoni, J.G. Pickering, T.P. Johnson, Putative autoantigen leiomodion-1 is expressed in the human brain and in the membrane fraction of newly formed neurons, *Pathogens.* 9 (2020) 1036, <https://doi.org/10.3390/pathogens9121036>.
- [16] M. Levite, D. Zelig, A. Friedman, N. Ilouz, R. Eilam, Z. Bromberg, A.A. Ramadhan Lasu, S. Arbel-Alon, S. Edvardson, M. Tarshish, L.P. Riek, R.L. Lako, B. Reubino, M. Lebendiker, D. Yaish, A. Stavsky, E. Galun, Dual-targeted autoimmune sword in fatal epilepsy: Patient's glutamate receptor AMPA GluR3B peptide autoimmune antibodies bind, induce reactive oxygen species (ROS) in, and kill both human neural cells and T cells, *J. Autoimmun.* 112 (2020), 102462, <https://doi.org/10.1016/j.jaut.2020.102462>.
- [17] G. Benedek, M. Abed El Latif, K. Miller, M. Rivkin, A.A. Ramadhan Lasu, L.P. Riek, R. Lako, S. Edvardson, S.A. Alon, E. Galun, M. Levite, Protection or susceptibility to devastating childhood epilepsy: Nodding Syndrome associates with immunogenetic fingerprints in the HLA binding groove, *PLoS Negl. Trop. Dis.* 14 (7) (2020 Jul 8) e0008436, <https://doi.org/10.1371/journal.pntd.0008436>.
- [18] P.S. Spencer, R. Mazumder, V.S. Palmer, M.R. Lasarev, R.C. Stadnik, P. King, M. Kabahenda, D.L. Kitara, D. Stadler, B. McArdle, J.K. Tumwine, other Members of the Oregon-Uganda Nodding Syndrome Research Team, Environmental, dietary and case-control study of nodding syndrome in Uganda: a post-measles brain disorder triggered by malnutrition? *J. Neurol. Sci.* 369 (2016) 191–203, <https://doi.org/10.1016/j.jns.2016.08.023>.
- [19] M. Roach, A. Cantu, M.K. Vieri, M. Cotten, P. Kellam, M. Phan, L.V. Hoek, M. Mandro, F. Tepage, G. Mambandu, G. Musinya, A. Laudisoit, R. Colebunders, R. Edwards, J.L. Mokili, No evidence known viruses play a role in the pathogenesis of onchocerciasis-associated epilepsy. An explorative metagenomic case-control study, *Pathogens.* 10 (2021) 787, <https://doi.org/10.3390/pathogens10070787>.
- [20] T. Piloya-Were, B. Odongkara-Mpora, H. Namusoke, R. Idro, Physical growth, puberty and hormones in adolescents with nodding syndrome; a pilot study, *BMC Res. Notes* 7 (2014) 858.
- [21] A.A. Denis, P. Galloway, A. Collines, M.E. Frederick, D.P.K.L. David, Metabolic analysis of nodding syndrome in Uganda: a pilot study is a biotinidase and acetyl carnitine deficiency; a metabolic disorder. An observational study design, *World J. Pharm. Med. Res.* 4 (2018) 160–174.
- [22] D.L. Kitara, A.D. Mwaka, E. Kigonya, High anion gap metabolic acidosis among children with nodding syndrome (NS) in northern Uganda: case series, *Br J Med Res* 4 (2014) 1301–1314.
- [23] G. Shepherd, C. Kazoora, Forests, Livelihood and Poverty Alleviation: The Case of Uganda, Food and Agricultural Organization, Rome, 2013, p. 14.
- [24] UNHCR-USA, UNHCR closes chapter on Uganda's internally displaced people, UN Refugee Agency, January 6, 2012. <https://www.unhcr.org/en-us/news/briefing/2012/1/4f06e2a79/unhcr-closes-chapter-ugandas-internally-displaced-people.html> (accessed 12/31/2021).
- [25] R. Das, A. Nkutu, Evaluation of General Food Distribution in Northern Uganda: Gulu, Amur and Kitgum Districts 2005–2008. Evaluation Report, Nordic Consulting Group, Norwegian Refugee Council, June 2008.
- [26] J.L. Foltz, I. Makumbi, J.J. Sejvar, M. Malimbo, R. Ndyomugenyi, A.D. Atai-Omoruto, L.N. Alexander, B. Abang, P. Melstrom, A.M. Kakooza, D. Olara, R. G. Downing, T.B. Nutman, S.F. Dowell, D.K. Lwamafa, An epidemiologic investigation of potential risk factors for nodding syndrome in Kitgum District, Uganda, *PLoS One.* 8 (2013), e66419, <https://doi.org/10.1371/journal.pone.0066419>.
- [27] J.J. Sejvar, A.M. Kakooza, J.L. Foltz, I. Makumbi, A.D. Atai-Omoruto, M. Malimbo, R. Ndyomugenyi, L.N. Alexander, B. Abang, R.G. Downing, A. Ehrenberg, K. Guilliams, S. Helmers, P. Melstrom, D. Olara, S. Perlman, J. Ratto, E. Trevathan, A.S. Winkler, S.F. Dowell, D. Lwamafa, Clinical, neurological, and electrophysiological features of nodding syndrome in Kitgum, Uganda: an observational case series, *Lancet Neurol.* 12 (2013) 166–174, [https://doi.org/10.1016/S1474-4422\(12\)70321-6](https://doi.org/10.1016/S1474-4422(12)70321-6).
- [28] J.H. Obol, D.A. Arony, R. Wanyama, K.L. Moi, B. Bodo, P.O. Odong, M. Odida, Reduced plasma concentrations of vitamin B6 and increased plasma concentrations of the neurotoxin 3-hydroxykynurenine are associated with nodding syndrome: a case control study in Gulu and Amuru districts, Northern Uganda, *Pan Afr. Med. J.* 24 (2016) 123, <https://doi.org/10.11604/pamj.2016.24.123.8409>.
- [29] J.L. Landis, V.S. Palmer, P.S. Spencer, Nodding syndrome in Kitgum District, Uganda: association with conflict and internal displacement, *BMJ Open.* 4 (2014), e006195.
- [30] R. Echodu, H. Edema, G.M. Malinga, A. Hendy, R. Colebunders, J. Moriku Kaducu, E. Ovuga, G. Haesaert, Is nodding syndrome in northern Uganda linked to consumption of mycotoxin contaminated food grains? *BMC Res. Notes* 11 (2018) 678, <https://doi.org/10.1186/s13104-018-3774-y>.
- [31] J. Düringer, R. Mazumder, V. Palmer, A.M. Craig, P. Spencer, Case-control study of nodding syndrome in Acholiland: urinary multi-mycotoxin screening, *Toxins* (Basel). 13 (2021) 313, <https://doi.org/10.3390/toxins13050313>.
- [32] A. Dietmann, B. Wallner, R. König, K. Friedrich, B. Pfäusler, F. Deisenhammer, A. Griesmacher, C. Seger, W. Matuja, L. JilekAall, A.S. Winkler, E. Schmutzhard, Nodding syndrome in Tanzania may not be associated with circulating anti-NMDA- and anti-VGKC receptor antibodies or decreased pyridoxal phosphate serum levels: a pilot study, *Afr. Health Sci.* 14 (2014) 434–438, <https://doi.org/10.4314/ahs.v14i2.20>.
- [33] Z.T. Kincses, J. Toldi, L. Vécsei, Kynurenines, neurodegeneration and Alzheimer's disease, *J. Cell. Mol. Med.* 14 (2010) 2045–2054, <https://doi.org/10.1111/j.1582-4934.2010.01123.x>.
- [34] A.L. Colín-González, P.D. Maldonado, A. Santamaría, 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system, *Neurotoxicology.* 34 (2013) 189–204, <https://doi.org/10.1016/j.neuro.2012.11.007>.
- [35] M. González-Sánchez, J. Jiménez, A. Narváez, D. Antequera, S. Llamas-Velasco, A. H. Martín, J.A.M. Arjona, A.L. Munain, A.L. Bisa, M.P. Marco, M. Rodríguez-Núñez, D.A. Pérez-Martínez, A. Villarejo-Galende, F. Bartolome, E. Domínguez, E. Carro, Kynurenin acid levels are increased in the CSF of Alzheimer's disease patients, *Biomolecules.* 10 (2020) 571, <https://doi.org/10.3390/biom10040571>.
- [36] D.L. Kitara, L. Lemos, J.B. Bump, Nodding syndrome: an enigmatic neglected tropical disease, a newly recognized neurodegenerative disorder with regional clusters in East Africa; could it be an early-onset Alzheimer's disease? *PAMJ-Clin Med* 8 (2022).
- [37] D.M. Storey, Filariasis: nutritional interactions in human and animal hosts, *Parasitology.* 107 (Suppl) (1993) S147–S158, <https://doi.org/10.1017/s0031182000075570>.
- [38] R. Mazumder, K. Tabu, J. Engel, D. Kitara, P.S. Spencer, S. Olum, D. Eliashiv, Electrographic Features among Children with Nodding Syndrome, Asymptomatic Siblings and Unrelated Healthy Controls. 4th African Epilepsy Congress, Kampala, Uganda, 2019.
- [39] M. Gibaud, M. Barth, J. Lefranc, K. Mention, N. Villeneuve, M. Schiff, H. Maurey, M.A. Barthez, I. Caubel, M. Chouchane, D. Doumgar, M. Kossorotoff, M. D. Lamblin, A. Roubertie, R. Nabbout, P. Van Bogmaert, West syndrome is an exceptional presentation of pyridoxine- and pyridoxal phosphate-dependent epilepsy: data from a French cohort and review of the literature, *Front. Pediatr.* 9 (2021), 621200, <https://doi.org/10.3389/fped.2021.621200>.
- [40] M.A. Mikati, E. Trevathan, K.S. Krishnamoorthy, C.T. Lombroso, Pyridoxine-dependent epilepsy: EEG investigations and long-term follow-up, *Electroencephalogr. Clin. Neurophysiol.* 78 (1991) 215–221, [https://doi.org/10.1016/0013-4694\(91\)90035-3](https://doi.org/10.1016/0013-4694(91)90035-3).
- [41] G. de Polo, R. Romaniello, A. Otin, K. Benjamin, P. Bonanni, R. Borgatti, Neurophysiological and clinical findings on nodding syndrome in 21 south Sudanese children and a review of the literature, *Seizure.* 31 (2015) 64–71, <https://doi.org/10.1016/j.seizure.2015.07.006>.
- [42] R. Nabbout, C. Soufflet, P. Plouin, O. Dulac, Pyridoxine dependent epilepsy: a suggestive electroclinical pattern, *Arch. Dis. Child. Fetal Neonatal Ed.* 81 (1999) F125–F129, <https://doi.org/10.1136/fn.81.2.f125>.
- [43] B.B. N'guessan, S.K. Amponsah, I.B. Iheagwara, M.A. Seidu, S. Frimpong-Manso, E. Ofori-Attah, E.O. Bekoe, J.A. Sarkodie, R. Appiah-Opong, I.J. Asiedu-Gyekye, Toxicity, mutagenicity and trace metal constituent of *Termitomyces schimperi* (pat.) R. Heim (Lyophyllaceae) and kaolin, a recipe used traditionally in cancer management in cote d'Ivoire, *J. Ethnopharmacol.* 276 (2021), 114147, <https://doi.org/10.1016/j.jep.2021.114147>.
- [44] R. Walleya, J. Rammeloo, Poisonous and useful fungi of Africa south of the Sahara: A literature survey, Ministry of Agriculture, Administration of Agricultural Research, National Botanic Garden of Belgium, Meise, 1994, 56 p. (Scripta Bot Belg.10).
- [45] P. Baxter, Pyridoxine-dependent and pyridoxine-responsive seizures, *Dev. Med. Child Neurol.* 43 (2001) 416–420, <https://doi.org/10.1017/s0012162201000779>.
- [46] D.N. Pegler, A preliminary agaric flora of East Africa, *Kew Bull Addit Series* 6 (1977) 1–615.
- [47] J. Chen, R.-L. Zhai, L.A. Parra, A.K. Guelly, A. De Kesel, S. Rapior, K.D. Hyde, E. Chukeatiro, P. Callac, *Agaricus* section *Brunneopicti*: a phylogenetic reconstruction with descriptions of four new taxa, *Phytotaxa.* 192 (2015) 145–168, <https://doi.org/10.11646/phytotaxa.192.3.2>.
- [48] D.N. Pegler, A Preliminary Agaric Flora of East Africa. *Kew Bull. Addition. Series VI, Her Majesty's Stationery Office, London, 1977, p. 330.*
- [49] R. Malouf, Evans J. Grimley, The effect of vitamin B6 on cognition, *Cochrane Database Syst. Rev.* (2003) CD004393, <https://doi.org/10.1002/14651858.CD004393> (PMID: 14584010).
- [50] A. Lewy, N. Fox, Pyridoxine (B6) used in the treatment of vertigo, *Arch. Otolaryngol.* 46 (1947) 681–683, <https://doi.org/10.1001/archotol.1947.00690020697010>.
- [51] C. Hashida, K. Hayashi, L. Jie, S. Haga, M. Sakurai, H. Shimizu, Quantities of agaritine in mushrooms (*Agaricus bisporus*) and the carcinogenicity of mushroom methanol extracts on the mouse bladder epithelium, *Nihon Koshu Eisei Zasshi* 37 (1990) 400–405. Japanese. (PMID: 2132000).
- [52] V. Schulzova, J. Hajslova, R. Peroutka, J. Hlavasek, J. Gry, H.C. Andersson, Agaritine content of 53 *Agaricus* species collected from nature, *Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess.* 26 (2009) 82–93, <https://doi.org/10.1080/02652030802039903>.

- [53] UDHS, Uganda Demographic and Health Survey 2006. Uganda Bureau of Statistics Kampala, Uganda Macro International Inc, Calverton, Maryland, USA. August, 2007, p. p158.
- [54] K. Walton, M.M. Coombs, F.S. Catterall, R. Walker, C. Ioannides, Bioactivation of the mushroom hydrazine, agaritine, to intermediates that bind covalently to proteins and induce mutations in the Ames test, *Carcinogenesis*. 18 (1997) 1603–1608, <https://doi.org/10.1093/carcin/18.8.1603>.
- [55] K. Walton, M.M. Coombs, R. Walker, C. Ioannides, The metabolism and bioactivation of agaritine and of other mushroom hydrazines by whole mushroom homogenate and by mushroom tyrosinase, *Toxicology* 161 (2001) 165–177.
- [56] W.S. Bosan, R.C. Shank, Methylation of liver DNA guanine in hamsters given hydrazine, *Toxicol. Appl. Pharmacol.* 70 (1983) 324–334, [https://doi.org/10.1016/0041-008x\(83\)90108-4](https://doi.org/10.1016/0041-008x(83)90108-4).
- [57] B.H. Mathison, S.E. Murphy, R.C. Shank, Hydralazine and other hydrazine derivatives and the formation of DNA adducts, *Toxicol. Appl. Pharmacol.* 127 (1994) 91–98, <https://doi.org/10.1006/taap.1994.1143>.
- [58] E. Lagrange, J.P. Vernoux, Warning on false or true morels and button mushrooms with potential toxicity linked to hydrazinic toxins: an update, *Toxins (Basel)*. 12 (2020) 482, <https://doi.org/10.3390/toxins12080482>.
- [59] K. Hiramoto, M. Kaku, T. Kato, K. Kikugawa, DNA strand breaking by the carbon-centered radical generated from 4-(hydroxymethyl) benzenediazonium salt, a carcinogen in mushroom *Agaricus bisporus*, *Chem. Biol. Interact.* 94 (1995) 21–36, [https://doi.org/10.1016/0009-2797\(94\)03315-y](https://doi.org/10.1016/0009-2797(94)03315-y).
- [60] F. Esclaire, G. Kisby, P. Spencer, J. Milne, M. Lesort, J. Hugon, The Guam cycad toxin methylazoxymethanol damages neuronal DNA and modulates tau mRNA expression and excitotoxicity, *Exp. Neurol.* 155 (1999) 11–21, <https://doi.org/10.1006/exnr.1998.6962>.
- [61] G.E. Kisby, R.C. Fry, M.R. Lasarev, T.K. Bammler, R.P. Beyer, M. Churchwell, D. R. Doerge, L.B. Meira, V.S. Palmer, A.L. Ramos-Crawford, X. Ren, R.C. Sullivan, T. J. Kavanagh, L.D. Samson, H. Zarbl, P.S. Spencer, The cycad genotoxin MAM modulates brain cellular pathways involved in neurodegenerative disease and cancer in a DNA damage-linked manner, *PLoS One*. 6 (2011), e20911, <https://doi.org/10.1371/journal.pone.0020911>.
- [62] P.S. Spencer, G.E. Kisby, Role of hydrazine-related chemicals in cancer and neurodegenerative disease, *Chem. Res. Toxicol.* 34 (2021) 1953–1969, <https://doi.org/10.1021/acs.chemrestox.1c00150>.
- [63] G.E. Kisby, P.S. Spencer, Genotoxic damage during brain development presages prototypical neurodegenerative disease, *Front. Neurosci.* 15 (2021), 752153, <https://doi.org/10.3389/fnins.2021.752153>.
- [64] M. Fenech, Vitamins associated with brain aging, mild cognitive impairment, and Alzheimer disease: biomarkers, epidemiological and experimental evidence, plausible mechanisms, and knowledge gaps, *Adv. Nutr.* 8 (2017) 958–970, <https://doi.org/10.3945/an.117.015610>.
- [65] A. Mielech, A. Puścion-Jakubik, R. Markiewicz-Żukowska, K. Socha, Vitamins in Alzheimer's disease -review of the latest reports, *Nutrients*. 12 (2020) 3458, <https://doi.org/10.3390/nu12113458>.
- [66] J.M. Zhuo, D. Praticò, Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet, *Exp. Gerontol.* 45 (2010) 195–201, <https://doi.org/10.1016/j.exger.2009.12.005>.
- [67] A. Di Meo, J.G. Li, C. Barrero, S. Meralli, D. Praticò, Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy, *Mol. Psychiatry* 24 (2019) 1696–1706, <https://doi.org/10.1038/s41380-018-0062-0>.
- [68] L.M. Aall-Jilek, Epilepsy in the Wapogoro tribe in Tanganyika, *Acta Psychiatr. Scand.* 41 (1965) 57–58.
- [69] S. Olum, P. Scolding, H. Hardy, J. Obol, N.J. Scolding, Nodding syndrome: a concise review, *Brain, Communications*. 2 (2020), fcaa037, <https://doi.org/10.1093/braincomms/fcaa037>.
- [70] B. Qian, S. Shen, J. Zhang, P. Jing, Effects of vitamin B6 deficiency on the composition and functional potential of T cell populations, *J. Immunol. Res.* 2017 (2017) 2197975, <https://doi.org/10.1155/2017/2197975>.
- [71] J. Wang, L. Chen, Y. Zhang, C.G. Li, H. Zhang, Q. Wang, X. Qi, L. Qiao, W.W. Da, X. J. Cui, S. Lu, Y.J. Wang, B. Shu, Association between serum vitamin B6 concentration and risk of osteoporosis in the middle-aged and older people in China: a cross-sectional study, *BMJ Open* 9 (2019), e028129, <https://doi.org/10.1136/bmjopen-2018-028129>.
- [72] N.S. Dhalla, S. Takeda, V. Elimban, Mechanisms of the beneficial effects of vitamin B6 and pyridoxal 5-phosphate on cardiac performance in ischemic heart disease, *Clin. Chem. Lab. Med.* 51 (2013) 535–543, <https://doi.org/10.1515/ccm-2012-0553>.
- [73] A.D. Volpe, A. Lucia, C. Pirozzi, V. Pastore, Comparative study between the use of melatonin and a solution with melatonin, tryptophan, and vitamin B6 as an inducer of spontaneous sleep in children during an auditory response test: an alternative to commonly used sedative drugs, *J. Int. Adv. Otol.* 13 (2017) 69–73, <https://doi.org/10.1512/iao.2017.3054>.
- [74] J.F. Mueller, Vilter., Pyridoxine deficiency in human being induced with desoxyypyridine, *J. Clin. Invest.* 29 (1950) 193–201, <https://doi.org/10.1172/JCI102246>.
- [75] M.J. Brown, M.A. Ameer, K. Beier, Vitamin B6 deficiency [Updated 2021 Jul 25], StatPearls Publishing, Treasure Island (FL), 2021.
- [76] R. Arsalan, S. Sabzwari, Isoniazid-induced motor-dominant neuropathy, *J. Pak. Med. Assoc.* 65 (2015) 1131–1133.
- [77] K.E. Anderson, J.E. Silver, VI nutritional factors, in: V.S. Ramachandran (Ed.), *Encyclopedia of the Human Brain*, Elsevier, New York, 2002, pp. 701–708.
- [78] K. Toriumi, M. Miyashita, K. Suzuki, N. Yamasaki, M. Yasumura, Y. Horiuchi, A. Yoshikawa, M. Asakura, N. Usui, M. Itokawa, M. Arai, Vitamin B6 deficiency hyperactivates the noradrenergic system, leading to social deficits and cognitive impairment, *Transl. Psychiatry* 11 (2021) 262, <https://doi.org/10.1038/s41398-021-01381-z>.
- [79] Anon., The role of growth hormone in the action of vitamin B6 on cellular transfer of amino acids, *Nutr. Rev.* 37 (1979) 300–301, <https://doi.org/10.1111/j.1753-4887.1979.tb06698.x>.
- [80] D.L. Kitara, D.A. Arony, S. Gazda, Nodding syndrome and autism spectrum disorder. Chapter 2, in: M. Fitzgerald (Ed.), *Autism Spectrum Disorders*, Intech Open, 2019, <https://doi.org/10.5772/intechopen.83530>.
- [81] A. Hotterbeekx, M.K. Vieri, M. Ramberger, A. Jozefzoon-Aghai, M. Mandro, F. Tepage, A. Dusabimana, S. Kumar-Singh, M.J. Titulaer, R. Colebunders, No evidence for the involvement of leiomodin-1 antibodies in the pathogenesis of onchocerciasis-associated epilepsy, *Pathogens*. 10 (2021) 845, <https://doi.org/10.3390/pathogens10070845>.
- [82] Anon, International Scientific Meeting on Nodding Syndrome, Kampala, Uganda, 30 July-1 August, 2012. Meeting Report, UK AID, CDC, WHO, Republic of Uganda, 2021.
- [83] M. Härkönen, Mwasumbu L. Niemelä, Tanzanian mushrooms. Edible, harmful and other fungi, in: Botanical Museum, Finnish Museum of Natural History, University of Helsinki, Norrlinna, 2003, p. 10.
- [84] C. Kaiser, T. Rubaale, E. Tukesiga, W. Kipp, G. Asaba, Case report: nodding syndrome, western Uganda, 1994, *Am. J. Trop. Med. Hyg.* 93 (2015) 198–202, <https://doi.org/10.4269/ajtmh.14-0838>.
- [85] K.M. Miehle, Comprehensive analysis of current knowledge of nodding syndrome, Dr med Dissertation Fakultät für Medizin der Technischen Universität München (2018) 91.
- [86] S. Metanmo, F. Boumédiène, P.M. Preux, R. Colebunders, J.N. Siewe Fodjo, E. de Smet, E. Yangatimbi, A.S. Winkler, P. Mbelesso, D. Ajzenberg, First description of nodding syndrome in the Central African Republic, *PLoS Negl. Trop. Dis.* 15 (2021), e0009430, <https://doi.org/10.1371/journal.pntd.0009430>.